Condensed Consolidated Statements of Operations - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
|
| Operating Expenses: | ||||
| Research and development | $ 555,010 | $ 355,051 | $ 1,019,515 | $ 590,815 |
| Research and development - related party | 14,500 | 12,500 | 29,000 | 47,975 |
| General and administrative | 464,367 | 627,548 | 1,038,034 | 1,477,665 |
| Total Operating Expenses | 1,033,877 | 995,099 | 2,086,549 | 2,116,455 |
| Loss From Operations | (1,033,877) | (995,099) | (2,086,549) | (2,116,455) |
| Other (Expense) Income: | ||||
| Interest expense | (63,313) | (140,305) | (111,725) | (396,688) |
| Interest expense - related parties | (130,049) | (22,540) | (248,402) | (47,044) |
| Amortization of debt discount | (23,151) | (155,169) | (89,688) | (277,932) |
| Amortization of debt discount - related party | (35,204) | (41,805) | ||
| Gain on forgiveness of accrued interest | 49,983 | |||
| Loss on extinguishment of notes payable | (49,718) | |||
| Total Other Expense | (251,717) | (318,014) | (491,620) | (721,399) |
| Net Loss | (1,285,594) | (1,313,113) | (2,578,169) | (2,837,854) |
| Dividend attributable to Series A and Series C preferred stockholders | (244,971) | (225,873) | (569,888) | (449,264) |
| Net Loss Applicable to Common Stockholders | $ (1,530,565) | $ (1,538,986) | $ (3,148,057) | $ (3,287,118) |
| Net Loss Per Common Share - Basic and Diluted | $ (0.04) | $ (0.05) | $ (0.09) | $ (0.10) |
| Weighted Average Common Shares Outstanding - Basic and Diluted | 34,438,057 | 32,663,482 | 34,419,213 | 32,610,275 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amortization of debt discount - related party. No definition available.
|
| X | ||||||||||
- Definition Gain on Forgiveness of accrued interest. No definition available.
|
| X | ||||||||||
- Definition Amount of interest expense incurred on a debt or other obligation to related party. No definition available.
|
| X | ||||||||||
- Definition Research and Developement related party. No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|